Intrexon reported $9.07M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agenus AGEN:US USD 208.35M 20.03M
Amgen AMGN:US USD 9.5B 4.3B
Anika Therapeutics ANIK:US USD 87.78M 3.62M
Arrowhead Research ARWR:US USD 108M 31.43M
AstraZeneca AZN:LN USD 4.46B 359M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Gilead Sciences GILD:US USD 6.94B 2.2B
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Heron Therapeutics HRTX:US USD 50.44M 1.83M
Immunogen IMGN:US USD 309.51M 64.36M
Intrexon XON:US USD 9.07M 34.78M
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Ligand Pharmaceuticals LGND:US USD 121.41M 116.13M
Macrogenics MGNX:US USD 83.99M 62.52M
Mannkind MNKD:US USD 54.31M 18.8M
Novartis NOVN:VX USD 8.73B 5.1B
Peregrine Pharmaceuticals PPHM:US USD 115.14M 11.03M
Rigel Pharmaceuticals RIGL:US USD 29.87M 2.66M
Sangamo Biosciences SGMO:US USD 94.57M 23.14M
Thermo Fisher Scientific TMO:US USD 2.92B 1.03B
Veracyte VCYT:US USD 170.11M 16.66M
Xencor XNCR:US USD 52.65M 3.24M
YTE INCY:US USD 2.69B 255.24M
Ziopharm Oncology ZIOP:US USD 37.81M 22.2M